Response to neoadjuvant chemotherapy according to molecular subtypes in muscle-invasive bladder carcinoma. Comparison of pre- and post-TMT Signatera results.
Assessing real-world recurrence in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) treated with bacillus Calmette-Guérin (BCG) in the United States through a recurrence algorithm: A ...